Soleno Therapeutics Inc
Performance History
| Key Stats | |
|---|---|
| Open | $27.35 |
| Prev. Close | $27.47 |
| EPS | -3.21 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 8, 2023 |
| Dividend Yield % | - |
| Market Cap | $867.09M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 26.84 | 28.61 |
| 52 Week Range | 0.85 | 30.30 |
| Ratios | |
|---|---|
| P/B Ratio | 36.08 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | -$33.17M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -172.71% |
| EPS | -3.21 |
Score Breakdown
All Score (63 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| SLNO | Market | |
|---|---|---|
| Value | 58 | 42 |
| Quality | 32 | 46 |
| Ownership | 65 | 39 |
| Growth | 87 | 44 |
| Dividends | - | 32 |
All Score (63 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Soleno Therapeutics Inc (SLNO)
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Anish Bhatnagar M.D.
- Headquarters
- Redwood City
- Employees
- 25
Keep an eye on Soleno Therapeutics Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.